ERBB2 and cancer: Traditionally selected overexpressed cancer cell surface markers for the active targeting of NPs include ανβ3 integrin, aminopeptidase N (CD13), lymphocyte homing receptor (CD44), programmed death ligand-1 (CD274), folate receptor protein, nucleolin receptor, epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), human epidermal growth factor receptor 2 (HER2), luteinizing hormone-releasing hormone (LHRH) receptor, and somatostatin receptors (SSTRs) [93].